What is the recommended dose of ferric carboxymaltose (iron replacement therapy) for an adult patient with restless leg syndrome and iron deficiency or insufficiency?

Recommended Dose of Ferric Carboxymaltose for RLS with Iron Deficiency

For adult patients with restless leg syndrome and iron deficiency (ferritin ≤75 ng/mL or transferrin saturation <20%), administer 1500 mg of ferric carboxymaltose as a single intravenous infusion over at least 30 minutes. 1, 2

Dosing Algorithm Based on Clinical Parameters

Standard RLS Dosing (Non-Anemic Patients)

• If hemoglobin >10 g/dL and weight ≥50 kg: Administer 1000 mg ferric carboxymaltose as a single dose over at least 15 minutes 3
• If hemoglobin >10 g/dL and weight <50 kg: Administer 500 mg as a single dose 3

RLS with Concurrent Iron Deficiency Anemia

• If hemoglobin ≤10 g/dL and weight ≥50 kg: Administer 1500 mg as a single dose over at least 30 minutes 3, 2
• If hemoglobin ≤10 g/dL and weight <50 kg: Administer 1000 mg as a single dose 3

The higher 1500 mg dose is specifically supported by a 2021 randomized, placebo-controlled trial demonstrating significant improvement in IRLS scores (-13.47 points) at 6 weeks in RLS patients with iron deficiency anemia, with 61% of patients remaining off RLS medications at 52 weeks 2. This represents the most recent high-quality evidence for RLS-specific dosing.

Administration Guidelines

• Infusion rate for doses ≤1000 mg: Administer over at least 15-20 minutes 3, 4
• Infusion rate for doses >1000 mg: Administer over at least 30 minutes 3
• Do NOT administer if hemoglobin >15 g/dL 3

Expected Clinical Response Timeline

• Earliest symptom improvement: As early as day 8 post-infusion 5
• Peak response assessment: Week 6 post-infusion 2, 6
• Hemoglobin increase: Should rise 1-2 g/dL within 4-8 weeks 3

A 2012 observational study using 500 mg ferric carboxymaltose showed clinically relevant improvement by day 8 in responders 5, while the 2021 RCT with 1500 mg demonstrated sustained benefit through 52 weeks 2. The higher dose appears more appropriate for patients with concurrent anemia.

Monitoring and Re-Treatment Strategy

• Initial follow-up: Check ferritin and transferrin saturation at 3 months post-infusion 3
• Do NOT check iron parameters within first 4 weeks (circulating iron interferes with assays) 3
• Long-term monitoring: Every 3-6 months for at least one year 3
• Re-treatment threshold: When ferritin drops below 100 μg/L or symptoms recur 3

Critical Pitfalls to Avoid

• Underdosing in anemic patients: The 500 mg dose used in earlier studies 5 is insufficient for patients with concurrent iron deficiency anemia; use 1500 mg instead 2
• Premature laboratory assessment: Checking iron studies before 4 weeks will show falsely elevated values 3
• Single-dose assumption: While many patients respond to a single infusion, approximately 39% may require additional treatment within one year 2
• Ignoring responder characteristics: Younger patients with lower baseline ferritin and fewer comorbidities respond better to IV iron 5

Integration with RLS Treatment Algorithm

The American Academy of Sleep Medicine strongly recommends IV ferric carboxymaltose for RLS patients with ferritin ≤75 ng/mL or transferrin saturation <20% (strong recommendation, moderate certainty) 1. This should be implemented before or concurrent with first-line alpha-2-delta ligands (gabapentin, pregabalin), as iron repletion may allow dose reduction or discontinuation of RLS medications 1, 2.

A 2024 multicenter RCT using 750 mg on days 0 and 5 (total 1500 mg) showed significant IRLS score reduction versus placebo (-8.0 vs -4.8 points, p=0.0036), with fewer patients requiring ongoing RLS medications (32.7% vs 59.4%) 6. This split-dose regimen is an alternative to single-dose administration.